S. Sharma

1.2k total citations
27 papers, 554 citations indexed

About

S. Sharma is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, S. Sharma has authored 27 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in S. Sharma's work include Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Histone Deacetylase Inhibitors Research (3 papers). S. Sharma is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Histone Deacetylase Inhibitors Research (3 papers). S. Sharma collaborates with scholars based in United States, India and Canada. S. Sharma's co-authors include Bret J. Stephens, Stephen L. Lessnick, Savita Sankar, David J. Bearss, Rupeng Zhuo, Russell Bell, Baohua Sun, Kapil N. Bhalla, Warren Fiskus and Raffaella Soldi and has published in prestigious journals such as SHILAP Revista de lepidopterología, JNCI Journal of the National Cancer Institute and Oncogene.

In The Last Decade

S. Sharma

26 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Sharma United States 11 335 211 175 76 62 27 554
Joslyn Mills United States 9 279 0.8× 355 1.7× 251 1.4× 21 0.3× 75 1.2× 9 631
T Flores Spain 9 232 0.7× 143 0.7× 228 1.3× 124 1.6× 90 1.5× 21 570
C. Ormazábal Spain 9 283 0.8× 85 0.4× 159 0.9× 68 0.9× 204 3.3× 12 498
Lisbeth Haugom Norway 13 192 0.6× 206 1.0× 75 0.4× 35 0.5× 104 1.7× 19 486
Shashikant Kulkarni United States 5 170 0.5× 136 0.6× 67 0.4× 126 1.7× 142 2.3× 8 453
Justine N. McCutcheon United States 11 204 0.6× 107 0.5× 304 1.7× 22 0.3× 99 1.6× 16 680
Kristie Lawhorn United States 6 147 0.4× 175 0.8× 294 1.7× 32 0.4× 62 1.0× 11 459
Marco Bono Italy 14 189 0.6× 125 0.6× 185 1.1× 23 0.3× 133 2.1× 33 446
Yuri Miyazawa Japan 10 223 0.7× 54 0.3× 160 0.9× 55 0.7× 69 1.1× 33 464
Iker Antón Spain 9 305 0.9× 93 0.4× 225 1.3× 39 0.5× 214 3.5× 15 538

Countries citing papers authored by S. Sharma

Since Specialization
Citations

This map shows the geographic impact of S. Sharma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Sharma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Sharma more than expected).

Fields of papers citing papers by S. Sharma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Sharma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Sharma. The network helps show where S. Sharma may publish in the future.

Co-authorship network of co-authors of S. Sharma

This figure shows the co-authorship network connecting the top 25 collaborators of S. Sharma. A scholar is included among the top collaborators of S. Sharma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Sharma. S. Sharma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sharma, S., et al.. (2025). COMPARATIVE EVALUATION BETWEEN INTRATHECAL HYPERBARIC ROPIVACAINE 0.75% ALONE VERSUS INTRATHECAL HYPERBARIC ROPIVACAINE 0.75% AND DEXMEDETOMIDINE IN LOWER ABDOMINAL SURGERIES. International Journal of Current Pharmaceutical Research. 46–49. 1 indexed citations
2.
Ornellas, Antônio Augusto, Gilda Alves, S. Sharma, et al.. (2024). Amplification of different satellite-DNAs in prostate cancer. Pathology - Research and Practice. 256. 155269–155269. 3 indexed citations
3.
Shrestha, Gentle Sunder, et al.. (2024). Evaluation of the Effects of a Combination of Vitamin C, Thiamine and Hydrocortisone vs Hydrocortisone Alone on ICU Outcome in Patients with Septic Shock: A Randomized Controlled Trial. Indian Journal of Critical Care Medicine. 28(12). 1147–1152. 1 indexed citations
4.
5.
Tan, Daniel S.W., Michael Thomas, Dongwook Kim, et al.. (2021). Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. Lung Cancer. 163. 7–13. 7 indexed citations
6.
7.
Stenehjem, David D., Sumati Gupta, Mark Wade, et al.. (2016). A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies. Annals of Oncology. 27. vi367–vi367. 1 indexed citations
8.
Gupta, Sumati, et al.. (2016). Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells. Prostate Cancer and Prostatic Diseases. 19(4). 349–357. 40 indexed citations
9.
Saenz, Dyana T., Warren Fiskus, Taghi Manshouri, et al.. (2016). BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 31(3). 678–687. 64 indexed citations
10.
Kang, Yoon‐Koo, Min‐Hee Ryu, Yong Sang Hong, et al.. (2016). A phase II study of apatinib, a highly selective inhibitor of VEGFR-2, in patients with metastatic solid tumors without standard treatment options. Annals of Oncology. 27. vi119–vi119. 6 indexed citations
11.
Fiskus, Warren, S. Sharma, Saikat Saha, et al.. (2014). Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 29(6). 1267–1278. 82 indexed citations
12.
13.
Krug, Lee M., Agnieszka Woźniak, Hedy L. Kindler, et al.. (2014). Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer. 85(3). 429–434. 23 indexed citations
14.
Garrido‐Laguna, Ignacio, Kimberly McGregor, Mark Wade, et al.. (2013). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Investigational New Drugs. 31(5). 1257–1264. 56 indexed citations
15.
Sankar, Savita, Russell Bell, Bret J. Stephens, et al.. (2012). Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene. 32(42). 5089–5100. 118 indexed citations
16.
Jones, Kevin B., Le Su, R. Lor Randall, et al.. (2012). SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. Oncogene. 32(18). 2365–2371. 32 indexed citations
17.
Tolner, Berend, RB Pedley, Kerry Chester, et al.. (2009). Data standards for minimum information collection for antibody therapy experiments. Protein Engineering Design and Selection. 22(3). 221–224. 6 indexed citations
18.
Shah, Gaurang, et al.. (1999). Ocular hypotensive effect of ramiprilat in chronic and acute models of glaucoma in rabbits. Indian Journal of Pharmacology. 31(2). 110–115. 5 indexed citations
19.
Pandey, Anupam, et al.. (1994). An iterative approach for the soil-structure interaction in tall buildings. Engineering Fracture Mechanics. 47(2). 169–176. 2 indexed citations
20.
Sharma, S., et al.. (1985). USE OF NONLINEAR OPTIMIZATION TECHNIQUES IN DETERMINING THE OPTIMAL DESIGN OF INTZE TANKS ON SHAFTS. Engineering Optimization. 9(2). 143–153. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joslyn Mills Breakdown of academic impact, for papers by T Flores Breakdown of academic impact, for papers by C. Ormazábal Breakdown of academic impact, for papers by Lisbeth Haugom Breakdown of academic impact, for papers by Shashikant Kulkarni Breakdown of academic impact, for papers by Justine N. McCutcheon Breakdown of academic impact, for papers by Kristie Lawhorn Breakdown of academic impact, for papers by Marco Bono Breakdown of academic impact, for papers by Yuri Miyazawa Breakdown of academic impact, for papers by Iker Antón
Rankless by CCL
2026